Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010;3(3):228-33.
doi: 10.3980/j.issn.2222-3959.2010.03.11. Epub 2010 Sep 18.

Cost-effectiveness of autologous retinal pigment epithelium and choroid translocation in neovascular AMD

Aljoscha S Neubauer  1 , Sandra Liakopoulos, Jan C van Meurs, Bernd Kirchhof
Affiliations

Cost-effectiveness of autologous retinal pigment epithelium and choroid translocation in neovascular AMD

Aljoscha S Neubauer et al. Int J Ophthalmol. 2010.

Abstract

Aim: To assess the cost-effectiveness of autologous retinal pigment epithelium and choroid translocation (PATCH) in neovascular age-related macular degeneration (AMD).

Methods: Visual acuity and complication rates of published patient series were used to determine the incremental utility of treatment for the patient. The utility data applied assume that the better eye was affected. Comparator was a meta-analysis of recent control groups, in which patients received best supportive care. To assess cost-effectiveness, costs per quality adjusted life years (QALYs) and costs of avoiding low vision ("legal blindness", i.e. ≤20/200) were calculated. Costs were based on a German sick fund perspective and in a scenario on US costs. Robustness of the model was investigated by univariate and probabilistic multivariate sensitivity analysis (PSA).

Results: Cost-utility analysis showed surgery to be the dominant ("cost-saving") strategy for Germany and for the US in both, cost-effectiveness and cost-utility analysis (costs per QALY). In the sensitivity analysis the intervention remained dominant or cost-effective in all scenarios investigated. Clinical outcomes and duration of modeling were the most influential factors in the sensitivity analyses.

Conclusion: Therapy of neovascular AMD by PATCH is a cost-effective treatment option for selected patients, who are not well suitable for other current treatment options.

Keywords: QALY; age-related macular degeneration; choroidal neovascularization; cost-utility analysis; macular surgery.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Model structure
A combined decision tree (for year 1) and Markov model (for year 2-n) was applied to model cost-effectiveness. Detailled clinical data and costing sources are described in the methods section. The (M) marks those nodes in the decision tree, where the Markov long-term model part starts. Patients may transition to death from any Markov state. The two Markov states [0.05-0.1] and <0.05 together represent “legal blindness” as used in cost-effectiveness modeling
Figure 2
Figure 2. Probabilistic sensitivity analysis
The graph gives the likelihood of the surgical intervention to be below a given threshold for cost-effectiveness. It can be seen, that therapy is cost-effective even for low thresholds, e.g. >=90% probability for 6'874 �/QALY
See this image and copyright information in PMC

References

    1. Lotery A, Xu X, Zlatava G, Loftus J. Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study. Br J Ophthalmol. 2007;91(10):1303–1307. - PMC - PubMed
    1. Soubrane G, Cruess A, Lotery A, Pauleikhoff D, Monès J, Xu X, Zlateva G, Buggage R, Conlon J, Goss TF. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Arch Ophthalmol. 2007;125(9):1249–1254. - PubMed
    1. Brown MM, Brown GC, Sharma S, Stein JD, Roth Z, Campanella J, Beauchamp GR. The burden of age-related macular degeneration: a value-based analysis. Curr Opin Ophthalmol. 2006;17(3):257–266. - PubMed
    1. Knauer C, Pfeiffer N. Blindness in Germany--today and in 2030. Ophthalmologe. 2006;103(9):735–741. - PubMed
    1. Neubauer AS, Welge-Lüssen UC, Thiel MJ, Alge C, Priglinger SG, Hirneiss C, Ulbig MW, Kampik A. Tele-screening for diabetic retinopathy with the retinal thickness analyzer. Diabetes Care. 2003;26(10):2890–2897. - PubMed

LinkOut - more resources